---
title: "Pre-market hot trades in US stocks: Altisource Portfolio up 7.89% in pre-market; JE Cleantech up 7.26% in pre-market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276744080.md"
description: "Altisource Portfolio pre-market up 7.89%; JE Cleantech pre-market up 7.26%; Ten-League pre-market up 55.00%; Vir Biotechnology pre-market up 36.20%; Palvella Therapeutics pre-market up 29.78%"
datetime: "2026-02-24T13:47:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276744080.md)
  - [en](https://longbridge.com/en/news/276744080.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276744080.md)
generator: "portal-rs"
---

# Pre-market hot trades in US stocks: Altisource Portfolio up 7.89% in pre-market; JE Cleantech up 7.26% in pre-market

**Pre-market Hot Trades in US Stocks**

Altisource Portfolio, up 7.89% in pre-market trading, has no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

JE Cleantech, up 7.26% in pre-market trading, has no significant news recently. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

**Top Gainers in Pre-market US Stocks**

Ten-League is up 55% in pre-market trading. Ten-League is up 55% in pre-market trading. There is no significant news recently; the trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news

Vir Biotechnology is up 36.20% in pre-market trading. Based on recent key news:

1.  On February 24, Vir Biotechnology reached a collaboration agreement with Astellas Pharma to advance the development and commercialization of its prostate cancer experimental drug VIR-5500. The agreement includes a $335 million upfront payment and recent milestone payments, which are expected to have a significant impact on the company's future growth. Source: Reuters

2.  On February 24, Vir Biotechnology reported fourth-quarter revenue of $64 million, far exceeding analysts' expectations of $23.1 million, demonstrating strong financial performance. Source: Reuters

3.  On February 24, Vir Biotechnology's Phase I clinical trial results for VIR-5500 were positive, showing good safety and anti-tumor activity, further boosting market confidence. Source: Reuters The biotechnology industry faces regulatory risks, and the market is highly volatile.

Palvella Therapeutics is up 29.78% in pre-market trading. Based on recent key news:

1.  On February 24, Palvella Therapeutics announced positive topline results in its Phase III clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations. The trial met its primary endpoint and achieved statistical significance on all four secondary efficacy endpoints (P<0.001), driving the stock price up. Source: Reuters

2.  On February 24, the company plans to submit a new drug application to the FDA in the second half of 2026, with approval expected in the first half of 2027. This news has enhanced market confidence in the company's future development. Source: Reuters

3.  On February 24, Palvella Therapeutics' QTORIN™ rapamycin performed well in the trial, with no serious adverse events, further solidifying investors' confidence in the safety of its products Source: Reuters The biopharmaceutical industry has performed strongly recently, with significant capital inflows

### Related Stocks

- [ASPS.US](https://longbridge.com/en/quote/ASPS.US.md)
- [JCSE.US](https://longbridge.com/en/quote/JCSE.US.md)

## Related News & Research

- [Altisource Portfolio Solutions (NASDAQ:ASPS) Director Matthew Winkler Acquires 2,000 Shares](https://longbridge.com/en/news/296887795.md)
- [Benefit Street Partners acquires $288,728 of Altisource Portfolio Solutions common shares](https://longbridge.com/en/news/294878991.md)
- [Altisource Portfolio director Matthew T. Winkler buys $8,625.50 in common shares](https://longbridge.com/en/news/294535519.md)
- [Altisource Portfolio Solutions Chair, CEO William Shepro acquires common shares worth $20,720](https://longbridge.com/en/news/294224285.md)
- [Luxembourg's Altisource Q2 service revenue rises on customer wins](https://longbridge.com/en/news/293605745.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**